CN112891360A

CN112891360A - New application of deoxyrhaponticin

Info

Publication number: CN112891360A
Application number: CN202110310370.5A
Authority: CN
Inventors: 孙铭飞; 廖申权; 戚南山; 林栩慧; 吕敏娜; 吴彩艳; 李娟�; 蔡海明; 胡俊菁; 肖文婉; 于林增; 张小慧; 张健騑; 谢明权
Original assignee: Institute of Animal Health of Guangdong Academy of Agricultural Sciences
Current assignee: Institute of Animal Health of Guangdong Academy of Agricultural Sciences
Priority date: 2021-03-23
Filing date: 2021-03-23
Publication date: 2021-06-04
Anticipated expiration: 2041-03-23
Also published as: CN112891360B

Abstract

The invention relates to the technical field of animal disease prevention and control, in particular to a new application of deoxyrhapontin, and specifically relates to an application of deoxyrhapontin in preparation of anti-coccidiosis drugs or feeds. Compared with the prior art, the invention has the following beneficial effects: the invention discovers that the deoxyrhapontin has obvious inhibition effect on coccidian, the inhibition effect is embodied in that the deoxyrhapontin can effectively inhibit the propagation of the eimeria coccidian on a cell culture model of the eimeria coccidian, and the inhibition effect is verified by animal body tests. Aiming at the discovery of the deoxyrhaponticin, the application field of the deoxyrhaponticin is widened, and a new scheme is provided for the development of anticoccidial drugs.

Description

New application of deoxyrhaponticin

Technical Field

The invention relates to the technical field of animal disease prevention and control, in particular to a new application of deoxyrhaponticin.

Background

Deoxyrhaponticin (also called deoxyrhaponticin) with molecular weight of 404.41 and CAS number of 30197-14-9 is an alcohol extract of radix Et rhizoma Rhei with molecular formula of C₂₁H₂₄O₈The chemical structural formula is shown as follows:

the deoxyrhaponticin is mainly derived from Polygonaceae plant of radix et rhizoma Rhei, and is a symmetrical stilbene glycoside.

The existing research shows that the rhaponticin has antibacterial and antioxidant effects. According to reports, the functions of the rhaponticin comprise reducing blood fat, reducing blood sugar, resisting tumors and thrombus, inhibiting anaphylactic reaction, improving microcirculation and improving immunity of organisms.

Coccidiosis in chickens is a disease caused by infection with one or more species of eimeria, which are protozoa of the phylum apicomplexa, class sporozoea, order coccidioideae, family eimeria, genus eimeria. There are 7 species of Eimeria tenella (Eimeria tenella), Eimeria necatrix (e.necatrix), Eimeria brunetti (e.brunetti), Eimeria acervulina (e.acervulina), Eimeria maxima (e.maxima), Eimeria mitis (e.mitis) and Eimeria praecox (e.praecox), respectively.

Eimeria causing coccidiosis in chickens mainly includes eimeria tenella (e.tenella), eimeria necatrix (e.necatrix). After the chicken only infected with the Eimeria, the production performance is seriously reduced, even death is caused, and serious economic loss is brought to the chicken industry. Eimeria tenella (e.tenella) is one of the most harmful species, and after infection of a chicken, the chicken parasitizes in the caecum, resulting in clinical symptoms of bloody stool, anorexia, weight gain reduction and the like.

At present, the prevention and control of chicken coccidiosis at home and abroad mainly depends on medicines, the used medicines comprise two types of chemically synthesized medicines and antibiotics, and since the first appearance of special anticoccidial medicines in 1936, more than 40 anticoccidial medicines are reported, and 20 anticoccidial medicines are widely used at present. The traditional preventive drugs include proguanil, amproline, dinitolmide, monensin, salinomycin, diclazuril, maduramycin, clopyralid, nicarbazin, and the like. The traditional therapeutic drugs include toltrazuril solution, sulfonamides (such as sulfaquinoxaline and sulfaclozine sodium) and the like.

The prevention and treatment of the chicken coccidiosis depend on the use of the anticoccidial drugs, and the effect of the original anticoccidial drugs is obviously reduced along with the generation of the drug resistance of the clinical wild toxid strains to the traditional anticoccidial drugs, so that the anticoccidial drugs with definite treatment effects are lacking clinically. Therefore, a new anti-coccidiosis drug is urgently needed, and with the development needs of animal husbandry aquaculture and public health safety, the market demand for the new anti-coccidiosis drug will increase.

Disclosure of Invention

Based on the above, the main purpose of the invention is to provide a new application of the deoxyrhapontin, in particular to the application of the deoxyrhapontin in preparing anti-coccidiosis drugs or feeds, the deoxyrhapontin can effectively inhibit the breeding of coccidian and has obvious anti-coccidiosis effect.

The purpose of the invention is realized by the following technical scheme:

use of deoxyrhaponticin in preparing medicine or feed for resisting coccidiosis is provided.

In one embodiment, the coccidiosis is chicken coccidiosis.

In one embodiment, the infectious protozoan of chicken coccidiosis is eimeria tenella.

In one embodiment, the chicken breed infected with the chicken coccidiosis is green south yellow broiler.

In one embodiment, the medicament comprises deoxyrhapontin and pharmaceutically acceptable auxiliary materials.

In one embodiment, the mode of administration of the drug is by mass administration.

In one embodiment, the medicament is in the form of a powder.

In one embodiment, the medicament is in the form of a water-soluble powder.

In one embodiment, the medicament is in the form of a solution.

In one embodiment, the drug is in the form of microcapsules.

In one embodiment, the feed is a complete formula feed, a concentrated feed, a premix/premix feed, a concentrate mix, or a mixed feed.

Compared with the prior art, the application of the deoxyrhapontin in preparing the anti-coccidiosis drug or feed has the following beneficial effects:

according to the invention, research shows that the deoxyrhapontin has an obvious inhibition effect on coccidia (especially on Eimeria tenella), the inhibition effect is embodied in that the deoxyrhapontin can effectively inhibit the propagation of the Eimeria tenella on a cell culture model of the Eimeria tenella (such as MDBK cells), and the inhibition effect is verified by animal body tests. Aiming at the discovery, the application field of the deoxyrhaponticin is developed, and a solution is provided for the development of novel anticoccidial drugs.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.

FIG. 1 is a graph showing the effect of deoxyrhapontin on the reproduction of Eimeria tenella according to one embodiment of the present invention; in the figure, the abscissa is the concentration of the compound deoxyrhapontin, and the ordinate is the inhibition rate of the compound deoxyrhapontin on the propagation of Eimeria tenella;

FIG. 2 is a graph showing the effect of sulfachloropyrazine sodium on the propagation of Eimeria tenella according to one embodiment of the present invention; in the figure, the abscissa is the concentration of the compound sulfachloropyrazine sodium, and the ordinate is the inhibition rate of the compound sulfachloropyrazine sodium on the propagation of Eimeria tenella.

Detailed Description

In order that the invention may be more fully understood, reference will now be made to the following description. The present invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

The embodiment of the invention provides application of rhaponticin in preparation of anti-coccidiosis drugs or feeds.

The embodiment of the invention finds that the deoxyrhapontin has obvious inhibition effect on coccidium (especially on Eimeria tenella), the inhibition effect is embodied in that the deoxyrhapontin can effectively inhibit the propagation of the Eimeria tenella on a culture model of Eimeria tenella cells (such as MDBK cells), and the inhibition effect is verified by animal body tests. Aiming at the discovery of the deoxyrhaponticin, the application field of the deoxyrhaponticin is widened, and a new scheme is provided for the development of anticoccidial drugs.

It will be appreciated that the "chicken coccidiosis" described in the examples of the present invention is a parasitic disease which can result in significant economic losses in poultry production. Eimeria tenella parasitizes in chicken cecal epithelial cells, causing intestinal tract tissue lesion, reducing feed intake and absorption rate of nutrients in feed, dehydration, bloody stool and the like. Coccidiosis in chickens is caused by infection with one or more species of Eimeria (Eimeria) coccidia.

It is to be understood that the "Drugs" described in the examples of the present invention are Veterinary Drugs, and the "Veterinary Drugs (Veterinary Drugs)" described in the examples of the present invention: means a substance (drug-containing feed additive) for preventing, treating, diagnosing animal diseases or purposefully regulating animal physiological functions.

The anti-coccidiosis in the embodiment of the invention can have an obvious treatment effect on the coccidiosis and also can have an obvious prevention effect on the coccidiosis. The therapeutic, prophylactic or preventative action includes, but is not limited to, inhibition of Eimeria's reproduction.

In a specific example, the coccidiosis is chicken coccidiosis.

In a specific example, the infectious protozoan of chicken coccidiosis is eimeria tenella.

In a specific example, the chicken breed infected with coccidiosis is green south yellow broiler.

In a specific example, the drug comprises deoxyrhapontin and pharmaceutically acceptable adjuvants. It is understood that the type of the selected adjuvant, the amount of the selected adjuvant, etc. are different according to the dosage form of the drug.

It will be appreciated that the mode of administration of the medicament described in the examples of the invention is by mass administration. Of course, administration other than mass administration may be used, or a combination of mass administration with other pharmaceutically acceptable administration may be used.

It is understood that the "population administration" described in the examples of the present invention includes, but is not limited to:

mixing water for administration: first, the solubility of the drug in water is known; secondly, the dosage of the medicine is calculated according to the drinking amount, and if the stability of the medicine in water is poor, a thirst medicine taking method can be considered;

a material mixing and administration method: the drug is mixed into the feed for free ingestion, but the drug and the feed must be mixed evenly, and a progressive dilution method can be adopted.

In addition to the two ways of "group administration" of "mixed administration" and "mixed administration" as exemplified in the embodiments of the present invention, other suitable and veterinary acceptable ways of "group administration" may be adopted, and a plurality of ways of "group administration" may be used in combination.

It is understood that the deoxyrhapontin can be combined with suitable types of excipients to prepare drugs with different forms (such as liquid, semi-solid, solid) and form different dosage forms, including but not limited to: powder (including premix), water-soluble powder (including water-diffusible powder and water-soluble granules), solution (mainly aqueous solution, also suspension, emulsion, etc.), and microcapsule.

The water soluble powder (including water diffusible powder and water soluble granule) is made up by using medicine and auxiliary material of cosolvent and suspension adjuvant. Adding into drinking water to dissolve the medicine, and uniformly dispersing for animals to drink. The advantages of the dosage form include: the mixture is relatively uniform. ② the medicine has good effect for preventing and treating group diseases, especially sick livestock and poultry often eat less (even no) and drink more water, which is very good for guaranteeing that the sick livestock and poultry can eat enough medicine.

Solution (including oral liquid, suspension, and emulsion) is prepared by dissolving medicine in water, and can be used for oral administration or topical application. The advantages of the dosage form include: adding into drinking water to dissolve the medicine, and uniformly dispersing for animals to drink. The advantages of the dosage form include: the mixture is relatively uniform. ② the medicine has good effect for preventing and treating group diseases, especially sick livestock and poultry often eat less (even no) and drink more water, which is very good for guaranteeing that the sick livestock and poultry can eat enough medicine.

Powder, a widely used pharmaceutical dosage form, is ground into a powder form that can be incorporated into feed or dissolved in water for feeding to animals. The advantages of the dosage form include: the compound is added into feed as additive for preventing and treating diseases. Saves labor and time, can be used as clinical medicine to be mixed in the feed, and can also be directly used in the feed production process. ② convenient to store. And the quality is relatively stable.

Microcapsules are microcapsules which are prepared by wrapping a drug (core material) with a natural or synthetic polymer material (capsule material) and have a diameter of 1-500 microns. The medicinal microcapsule can be made into powder, tablet, injection, ointment, etc. according to requirement. The advantages of the dosage form include: the microcapsule can prolong drug effect, improve drug stability or cover unpleasant odor of the drug.

In the above, the embodiment of the present invention is only an example of the kind of "dosage form", and it should be understood that this is not a specific limitation to the "dosage form", and besides the several dosage forms of "powder", "water-soluble powder", "solution", and "microcapsule" as examples in the embodiment of the present invention, the doxycycline can be prepared into other suitable and pharmaceutically acceptable veterinary dosage forms. And it can be understood that one dosage form or a combination of multiple dosage forms of the deoxyrhapontin can be selected for feeding in the actual culture process.

The embodiment of the invention does not specially limit the specific types of the feed, and can be complete compound feed, concentrated feed, premix/premix feed, concentrated feed and mixed feed. The complete mixed feed, concentrated feed, premixed feed and concentrated feed mixture are mixed based on the growth stage, physiological requirement, nutritive requirement and nutritive value of animal, and are produced in certain proportion.

The complete compound feed is prepared from energy feed, protein feed, mineral feed, vitamins, amino acids and trace element additive according to a specified feeding standard, and has comprehensive and balanced nutrition.

A concentrated feed is prepared from protein feed, mineral feed (calcium, phosphorus and edible salt), and additive premix by mixing at a certain ratio. Can not be directly fed, and can be fed after corn or other energy feed is added.

The premixed feed is a mixture of one or more kinds of trace additive material, carrier and diluent, and its trace components are premixed to distribute homogeneously in great amount of feed. The feed is a semi-finished product, and can not be directly fed.

The concentrated feed mixture is a supplement concentrated feed for nutrient deficiency, mainly comprises energy feed, protein feed and mineral feed, and can be directly fed.

The mixed feed is prepared by simply processing and mixing certain feed raw materials, is a primary mixed feed, and mainly considers nutritional indexes such as energy, protein, calcium, phosphorus and the like.

The novel use of deoxyrhapontin according to the present invention will be described in further detail with reference to the following specific examples. The starting materials used in the following examples are all commercially available products unless otherwise specified.

Example 1

This example provides a cellular level assay for rhaponticin as follows:

firstly, experimental materials:

(1) medicine preparation: rhaponticin and sulfachloropyrazine sodium were purchased from Merck.

(2) Coccidian oocysts: eimeria tenella (e.tenella) eurycosporulated oocysts were stored by the institute of animal health, academy of agricultural sciences, guangdong, and rejuvenated in coccidiless chicks before use.

(3) Cell: MDBK cells (i.e. bovine kidney cells), were maintained by the institute of animal health, academy of agricultural sciences, guangdong.

II, an experimental method:

in this example, the e.tenella (e.tenella) resistance effect was evaluated by using an e.tenella MDBK cell culture model, and the specific evaluation steps included:

(1) MDBK cells grown to a confluency of 80% or more were digested with 0.25% trypsin digestion solution at 4X 10⁵Cell concentration per well plated 12 well cell culture plates at 37 ℃ with 5% CO₂The culture box is used for culturing for 24 hours.

(2) When the cells in the 12-well culture plate are grown to a confluent state of 80% or more, 10X 10 cells are inoculated per well⁴Sporozoites/ml, medium was discarded after 4h, washed 3 times with PBS, suspended sporozoites washed off and 5% fetal bovine serum in MEM medium was added to each well.

(3) Grouping tests:

setting 5 drug concentration gradients (specifically 0.01 μ M, 0.1 μ M, 1 μ M, 10 μ M, and 100 μ M) for the drug group to be detected (adding deoxyrhapontin), and setting 3 repetitions for each concentration;

a positive control group (added with sulfachloropyrazine sodium) is provided with 5 drug concentration gradients, specifically 0.01 μ M, 0.1 μ M, 1 μ M, 10 μ M and 100 μ M, and each concentration is provided with 3 repetitions;

blank control group: and (3) adding the volumes of the drug to be detected and the positive control drug according to the volumes of the drug to be detected and the positive control group, and adding an equal volume of culture medium which is MEM culture medium of 5% fetal calf serum.

(4) Placing at 37 deg.C with 5% CO₂The culture box is continuously cultured, the culture medium is removed after 48 hours of culture, PBS is used for washing for 3 times, total RNA of samples of each hole is extracted, and the influence of each test medicament on the propagation of the Eimeria tenella (E.tenella) is detected by RT-PCR.

The Real-time PCR primers were as follows:

specifically amplifying Eimeria tenella (E.tenella) actin primer,

EtActin-F:5’-CACCACCGCCGAGAAAGA-3’(SEQ ID NO.1)，

EtActin-R:5’-GAACAACATTG-CCGTAGAGG-3’(SEQ ID NO.2)；

specific amplification host cell actin primer,

Bactin-F:5’-GGATGAGGCTCAGAGCAAGAGA-3’(SEQ ID NO.3)，

Bactin-R:5’-TCGTCCCAGTTGGTG-ACGAT-3’(SEQ ID NO.4)。

by Delta C_TMethods the effect of each test drug on the growth and development of eimeria tenella (e.tenella) at the cell culture level was calculated.

The Real-time PCR reaction system is shown in Table 1, and the Real-time PCR reaction program is shown in Table 2.

TABLE 1 Real-time RT-PCR reaction System

TABLE 2 Real-time PCR reaction procedure

Evaluation indexes are as follows: delta C of experimental and control groups was obtained by Real-time RT-PCR_T＝C_T[Et actin]-C_T[H actin]，ΔΔC_T＝ΔC_T[exp]-ΔC_T[ref]Finally, the effect of resisting the Eimeria tenella (E.tenella) of the medicament to be screened is obtained:

thirdly, experimental results:

respectively calculating the inhibition effect of the drug group to be detected and the positive control group drug on the Eimeria tenella (E.tenella), wherein the rhaponticin and the sulfaclozine sodium as the control drug have obvious inhibition effect on the propagation of the Eimeria tenella (E.tenella) (table 3), and the rhaponticin and the sulfaclozine sodium as the control drug have obvious inhibition effect on the MIC of the Eimeria tenella (E.tenella) (Table 3)₅₀The values were 34.61. mu.M and 43.18. mu.M, respectively. The result shows that the deoxyrhapontin has good effect of resisting eimeria tenella and is obviously superior to the sulfachloropyrazine sodium serving as a reference medicament.

TABLE 3 inhibition of coccidial reproduction at cellular level by each test drug

FIG. 1 is a graph of the effect of deoxyrhapontin on the reproduction of Eimeria tenella; in the figure, the abscissa is the concentration of the compound deoxyrhapontin, and the ordinate is the inhibition rate of the compound deoxyrhapontin on the propagation of Eimeria tenella; FIG. 2 is a graph of the effect of sulfachloropyrazine sodium on the propagation of Eimeria tenella; in the figure, the abscissa is the concentration of the compound sulfachloropyrazine sodium, and the ordinate is the inhibition rate of the compound sulfachloropyrazine sodium on the propagation of Eimeria tenella. As can be seen from fig. 1, with the increase of the concentration of the deoxyrhapontin, the effect of the deoxyrhapontin on inhibiting the propagation of eimeria tenella is enhanced, and the effect of the deoxyrhapontin has concentration dependence and has good activity on inhibiting the development and propagation of eimeria tenella (e.tenella).

Example 2

This example provides an animal level test of deoxyrhapontin, as follows:

firstly, experimental materials:

(1) the preparation of the doxycycline powder preparation comprises the following steps: mixing 1.5g of deoxyrhapontin (not less than 80%) and 98.5g of starch respectively.

(2) Control drugs: a conventional anticoccidial drug, Triplex coccidium powder (30% sulfachloropyrazine sodium), was produced by Norwalk animal health Limited, Shanghai.

(3) Coccidian oocysts: eimeria tenella (e.tenella) eurycosporulated oocysts were stored by the institute of animal health, academy of agricultural sciences, guangdong, and rejuvenated in coccidiless chicks before use.

(4) Chicks: lingnan yellow broiler chickens are provided by animal science research institute of Guangdong province academy of agricultural sciences and are raised in a sterilized special animal house; the chicken coop and the utensils are strictly disinfected, and the chicken coop can freely eat and drink purified water; before the test, the chicks are observed to have clinical symptoms and the feces are continuously checked for coccidian oocysts for later use for 2 days.

(5) Feed: the young feed is prepared by Xinnandu feed science and technology Limited company in Guangdong province, and does not contain any anticoccidial drugs.

II, an experimental method:

(1) grouping: the 150-ridge south yellow broiler was bred to 10 days old according to experimental grouping and treatment, weighed one by one, weak chicks and those with excessive weight were eliminated, the remaining chicks were randomly divided into 4 groups of 30 chicks each, and the total body weight of each group of chicks was approximately equal by appropriate adjustment.

(2) And (3) treatment: except for the normal daily feed of the group 1 (blank control), the chicks of the groups 2 to 4 were orally administrated with I.tenella (E.tenella) sporulated oocysts (I.tenella) at one time, 105/feather; on the day of attack, 3 rd to 4 th groups of the chickens were fed with feed containing anticoccidial drugs for 7 days, and the grouping conditions of the test chickens and the usage and dosage of the drugs are shown in table 4.

TABLE 4 Experimental grouping

(3) And (4) counting results:

observing and recording the mental state, feed intake, excrement condition and the like of the chicken flocks every day; weighing dead chicks, performing a autopsy, and scoring the lesion as +4 points if the chicks die due to Eimeria tenella (E.tenella) infection; weighing all chicks one by one on the 7 th day after infection, performing a dissection, and scoring for caecum lesion; and finally, calculating the weight gain and feed reward of each group of chicks.

The efficacy determination method and the standard anticoccidial index (ACI) were calculated according to the formula recommended by merck:

ACI ═ (relative rate of weight gain + survival) - (oocyst value + lesion value);

relative percent (%) gain (test group weight gain ÷ blank control group weight gain) × 100%;

survival (%) — (number of surviving chicks per group ÷ total number of chicks per group) × 100%.

Lesions were scored on a five-point scale:

firstly, no oocysts exist, and the caecum is normal and is divided into 0 point;

secondly, oocysts exist, the mucous membrane of the caecum is slightly thickened, and a small amount of intestinal contents scattered in bleeding or a small amount of blood sample is divided into +1 point;

③ 2 minutes for oocyst, thickening of caecum mucous membrane and obvious bleeding or obvious blood sample intestinal content;

fourthly, oocysts exist, mucous membranes of caecum thicken, and a large amount of blood clots or blood sample intestinal cores are present, and the score is + 3;

chicks died due to coccidiosis or had a large number of oocysts, the cecum appeared dark reddish brown (or the middle of the small intestine had punctate necrotic foci, the mucous membrane appeared crimson), the intestinal canal was enlarged significantly, and the content formed a significant blood sample intestinal core, which was +4 points.

Mean lesion score per group x 10.

Oocyst values are converted from number of oocysts per gram of fecal contents (OPG).

The drug effect judgment standard is as follows: ACI <120 is ineffective, 120-160 is weak effect, 160-180 is middle effect, more than 180 is strong effect.

Thirdly, experimental results:

(1) observation of clinical symptoms: on day 2 of the control group (group 2) inoculated with sporulated oocysts of eimeria tenella (e.tenella), test chickens developed depressed spirit with decreased feed intake and developed bloody stools and died on day 5. Groups 3 and 4 had a slight decrease in appetite on day 3 after inoculation with Eimeria tenella sporulated oocysts. Group 1 had good appetite and mental status during the experiment.

(2) Anticoccidial indexes of groups 1 to 4 were calculated, respectively, and the results are shown in Table 5. The anticoccidial index of the group 4 (desoxyrhapontin group) is higher than that of the group 3 (three-word coccidian powder) of the contrast medicament, and the anticoccidial index (ACI) of the group 4 can reach more than 170, so that the anticoccidial index has good effect of resisting the eimeria tenella (E.tenella), and is superior to the three-word coccidian powder of the conventional anticoccidial medicament.

TABLE 5 anticoccidial index of each group

In conclusion, the embodiment of the invention discloses that the deoxyrhapontin can be used for treating the infection of the Eimeria tenella, the application of the deoxyrhapontin is expanded, and a new anti-coccidiosis drug is developed. Cell level tests and animal tests are carried out in the embodiment of the invention, and the results show that the deoxyrhapontin has obvious effect of inhibiting the Eimeria tenella. The deoxyrhapontin provided by the embodiment of the invention can be used for preparing an anti-eimeria tenella medicine.

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Sequence listing

<110> institute of animal health of academy of agricultural sciences of Guangdong province

<120> novel use of deoxyrhapontin

<160> 4

<170> SIPOSequenceListing 1.0

<210> 1

<211> 18

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 1

caccaccgcc gagaaaga 18

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 2

gaacaacatt gccgtagagg 20

<210> 3

<211> 22

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 3

ggatgaggct cagagcaaga ga 22

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 4

tcgtcccagt tggtgacgat 20

Claims

1. Use of deoxyrhaponticin in preparing medicine or feed for resisting coccidiosis is provided.

2. Use of deoxyrhapontin according to claim 1 for the preparation of a medicament or feed against coccidiosis, wherein the coccidiosis is chicken coccidiosis.

3. Use of deoxyrhapontin according to claim 2 in the preparation of a medicament or feed against coccidiosis, wherein the infectious protozoa of coccidiosis in chicken is Eimeria tenella.

4. The use of deoxyrhapontin in the preparation of anti-coccidiosis drugs or feeds according to claim 2, wherein the chicken infected with the coccidiosis is green south yellow broiler.

5. The use of deoxyrhapontin according to any one of claims 1 to 4 in the preparation of a drug or feed for resisting coccidiosis, wherein the drug comprises deoxyrhapontin and pharmaceutically acceptable auxiliary materials.

6. Use of deoxyrhapontin according to any of claims 1 to 4 in the preparation of a medicament or feed for treating coccidiosis, wherein the medicament is administered by mass administration.

7. The use of deoxyrhapontin according to any one of claims 1 to 4 in the preparation of a medicine or feed for resisting coccidiosis, wherein the dosage form of the medicine is powder.

8. The use of deoxyrhapontin according to any one of claims 1 to 4 in the preparation of a drug or feed for resisting coccidiosis, wherein the drug is in the form of water-soluble powder.

9. The use of deoxyrhapontin according to any one of claims 1 to 4 in the preparation of anti-coccidiosis drugs or feeds, wherein the drug is in the form of solution.

10. The use of deoxyrhapontin according to any of claims 1 to 4 in the preparation of anti-coccidiosis drugs or feeds, wherein the drug is in the form of microcapsules.

11. Use of at least one of the deoxyrhapontin according to any one of claims 1 to 4 in the preparation of a medicament or feed for resisting coccidiosis, wherein the medicament is in the form of a tablet.

12. The use of deoxyrhapontin according to any one of claims 1 to 4 in the preparation of a drug or feed for resisting coccidiosis, wherein the feed is a complete formula feed, a concentrated feed, a premix/premix feed, a concentrate mixture or a mixed feed.